Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Staging Set to Launch DNA-Amplification Technology

NEW YORK, Nov. 11 - Molecular Staging tomorrow will launch new DNA-amplification technology that it claims can yield an "unlimited amount" of DNA from a few cells.


The technology, called Repli-g, is based on multiple-displacement technology it licensed from Yale University. Repli-g is "a substantial advancement over currently available whole genome-amplification methods, rapidly amplifying the genome with comprehensive loci coverage, minimal bias between any loci and yielding 10+ kb fragments in a simple, scalable reaction," Molecular Staging said in a statement in April..


Stephen Kingsmore, COO of Molecular Staging, said the technology "will be enormously valuable" for researchers for whom obtaining additional sample blood is either too expensive or "impossible."


Scientists will have the option either to send samples to Molecular Staging, which will perform the amplification, or to buy a Repli-f kit themselves, the company said.


Last week, Molecular Staging, of New Haven, Conn., said it won $100,000 in a pair SBIR grants from the US Department of Energy. The grants will help the firm develop methods for microbial DNA amplification using the multiple displacement-amplification technology, and a biomarker chip for osteoarthritis.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.